New Molecules in Clinical Development

Using a search of trials listed on clinicaltrials.gov, Dr. Gary Novack describes the status of new glaucoma drugs that are in phase 1, 2, or 3 trials. His search uncovered 2 drugs: latanoprostene bunod 0.024%, a prostaglandin-releasing nitric oxide, and netarsudil 0.02%, a Rho-kinase inhibitor with norepinephrine reuptake inhibition.